BPC-157, TB-500, sermorelin, CJC-1295, ipamorelin — peptides are among the fastest-growing categories in longevity and biohacking. BPC-157 in particular has striking animal data for tissue healing: tendon repair, gut healing, neuroprotection, and anti-inflammatory effects across dozens of rodent studies. But here’s the problem: there are almost no published human clinical trials. The compounds are unregulated, purity varies wildly, and the FDA has cracked down on compounding pharmacies selling them. The gap between the animal promise and the human evidence is enormous.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a naturally occurring protein in human gastric juice. It has been studied extensively in animal models, where it consistently demonstrates remarkable tissue-healing properties. In rodent studies, BPC-157 has accelerated healing of tendons, ligaments, muscles, bone fractures, skin wounds, corneal injuries, and intestinal damage. The mechanism appears to involve upregulation of vascular endothelial growth factor (VEGF), modulation of the nitric oxide system, and interaction with multiple growth factor pathways.
The animal evidence is genuinely impressive — and that’s precisely the problem. Impressive animal data has a poor track record of translating to human benefit. The majority of drugs that show promise in rodents fail in human trials. Without human RCTs, we are extrapolating from a species with fundamentally different pharmacokinetics, dosing requirements, and healing biology.
As of early 2026, the human clinical evidence for BPC-157 consists primarily of a small number of studies and case reports, mostly focused on gastrointestinal conditions (inflammatory bowel disease, ulcers) rather than musculoskeletal healing or longevity. These studies are generally small, short-term, and insufficient to support the broad healing claims being made in the biohacking community.
The disconnect between the enormous popularity of BPC-157 (it is one of the most discussed peptides in longevity forums) and the near-absence of human trial data is one of the most striking gaps in the entire longevity supplement landscape.
Peptides sold outside of regulated pharmaceutical channels have no quality assurance. Independent testing of commercially available peptide products has found products with incorrect peptide concentrations, contamination with other peptides or chemicals, bacterial endotoxins, and heavy metals. When you inject or consume an unregulated peptide, you are trusting a supply chain with no oversight.
The FDA has taken enforcement actions against compounding pharmacies selling BPC-157, and in 2024–2025 moved to restrict its availability through the compounding pathway. This has pushed many users toward grey-market online sources with even less quality control.
The GH secretagogue paradox: Growth hormone secretagogues (sermorelin, CJC-1295/ipamorelin) raise GH and IGF-1 levels. But elevated IGF-1 signaling is consistently associated with accelerated aging in longevity research — from C. elegans to centenarian studies. Low IGF-1 signaling is one of the most conserved longevity pathways in biology. Using GH secretagogues for “anti-aging” may be working against the very biology of longevity.
BPC-157 has the most compelling preclinical tissue-healing data of any peptide in the longevity space. But the human evidence is essentially absent, purity is unregulated, the FDA is restricting access, and the extrapolation from rodent to human healing is unreliable. For recovery and tissue healing, the evidence-based options (physical therapy, adequate protein, sleep, load management) have far stronger human data.
Peptides represent one of the most overhyped categories in longevity medicine. The animal data for BPC-157 is genuinely exciting, and it’s plausible that it will eventually demonstrate human benefit in rigorous trials. But we are not there yet. The current landscape — unregulated products, near-zero human trials, FDA crackdowns, purity concerns, and grey-market sourcing — means that using peptides for longevity or recovery involves accepting significant unknowns about efficacy, safety, and product quality.
If you’re recovering from an injury, work with a sports medicine physician or physical therapist. If you’re interested in peptides, discuss them with a knowledgeable physician who can source pharmaceutical-grade products and monitor your response. And temper expectations — what heals a rat tendon in 14 days may do nothing for yours.